FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C. 20549
-------------	------------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
--------------	--

OMB Number: 3235-0287 Estimated average burden hours per response: 0.5

	Check this box if no longer subject to
١	Section 16. Form 4 or Form 5
	obligations may continue. See
	Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

								` '												
1. Name and Address of Reporting Person*  HARRISON DONALD C				2 <u>F</u>	. Issue Enter	r Nan oM	ne <b>and</b> Ticke edics Inc	er or Tradi	ng Sy <mark>M</mark> ]	mbol	(Ch	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner								
(Last) (First) (Middle) 2800 PATTON ROAD					. Date (		rliest Transa	ction (Mo	nth/D	ay/Year)		Officer (give title Other (specify below)								
(Street) ST. PAUL MN 55113			4	. If Ame	endm	ent, Date of	Original F	Filed (	Month/Day/\	Line	6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person Form filed by More than One Reporting Person									
(City)	(S	tate)	(Zip)														, , ,			
		T	able I - Nor	n-Der	rivati	ive S	ecu	rities Acc	quired,	Dis	posed of,	or Bene	eficially	Owned						
1. Title of Security (Instr. 3)  2. Transplate (Month/D					Day/Year) if		Deemed cution Date, ny nth/Day/Year	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			5. Amount Securities Beneficiall Owned Fol Reported	y	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount (A) or (D)		Price	Transaction(s) (Instr. 3 and 4)				, ,		
Common	Stock													4,65	55		D			
Common Stock 12.			12/	/14/20	4/2010			С		216,802	2 A	\$0 <sup>(5)</sup>	335,5	335,560		I	Charter Life Sciences, L.P. <sup>(2)</sup>			
			Table II -					ties Acqu warrants,						Owned						
1. Title of Derivative Security (Instr. 3)	Derivative Conversion Date Execution Date, Gecurity or Exercise (Month/Day/Year) if any		4. Fransa Code ( 3)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable Expiration Date (Month/Day/Year)		е	le and 7. Title and Am of Securities Underlying Derivative Sec (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	derivativ Securitie Beneficia Owned Followin Reported	re es ally g	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)				
				c	Code	v	(A)	(D)			Expiration Date	Title	Amount or Number of Shares		Transact (Instr. 4)	ion(s)				
Warrants (right to buy)	\$23.68								04/23/200	)4 <sup>(1)</sup>	04/23/2011	Common Stock	169		169	)	D			
Warrants (right to buy)	\$2.76								12/12/200	05 <sup>(1)</sup>	12/12/2010	Common Stock	2,747		2,74	17	I	Charter Life Sciences, L.P. <sup>(2)</sup>		
Stock Option (Right to Buy)	\$48.01								03/25/200	08 <sup>(3)</sup>	03/25/2018	Common Stock	4,166		4,16	66	D			
Stock Option (Right to Buy)	\$11.58								05/05/200	)9 <sup>(4)</sup>	05/05/2019	Common Stock	1,666		1,66	66	D			
Stock Option (Right to Buy)	\$2.52								05/06/203	10 <sup>(4)</sup>	05/06/2020	Common Stock	1,666		1,66	66	D			
Series A NonVoting Convertible Preferred Stock	(5)	12/14/2010			С			216,802 <sup>(5)</sup>	09/30/20	010	(6)	Common Stock	216,80	2 \$0	0		I	Charter Life Sciences, L.P.		
Up Front Warrant	\$2.15								(7)		(6)	Common Stock	216,80	2	216,8	302	I	Charter Life Sciences,		

## **Explanation of Responses:**

- 1. Immediately exercisable.
- 2. The reporting person is managing partner of Charter Life Sciences, L.P. The reporting person disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest therein.
- 3. Vests as to 25% immediately and then 1/36th per month thereafter. The vesting stops when reporting person ceases to be a director, if that occurs before the grant is fully vested.
- 4. Vests as to 25% on date noted and thereafter in cumulative installments of 1/36th per month.
- 5. The Series A preferred stock automatically converted into EnteroMedics common stock on a 1-for-1 basis immediately after the completion of EnteroMedics' public offering on December 14, 2010 in accordance with terms of the Certificate of Designations.
- 6. Not Applicable
- 7. Exercisable six months from the date of issuance on 9/30/2010.

/s/ Greg S. Lea, Attorney-in-Fact 12/15/2010

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.